Abstract
Introduction: The COVID-19 pandemic significantly impacted the treatment of breast cancer. Management deviated from standard practice. The Association of Breast Surgery (ABS) advised - aim for day case surgery with priority given to: estrogen receptor (ER)-ve, HER2+ve, and pre-menopausal ER+ve patients. Neoadjuvant chemotherapy was advised for inoperable disease only. Oncoplastic procedures and breast reconstruction was not advised. ER+ves were to be considered for bridging endocrine treatment. We audited this change in practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
